AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

1. (Currently Amended) A stent comprising an effective amount of a c-Jun-N-terminal kinase ("JNK") Inhibitor and a nitric oxide release agent.

2. (Original) The stent of claim 1 having a coating comprising an effective amount of a JNK Inhibitor.

3. (Original) The stent of claim 1 comprising a material having an effective amount of a JNK Inhibitor incorporated therein.

4. (Original) The stent according to claim 1, wherein the JNK Inhibitor has the following formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof,

wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently from R_3;

R_2 is $-R_3$, $-R_4$, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$, $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$,$-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, heterocycle, heterocycloalkyl, $-C(=O)OR_8$, $-OC(=O)R_8$, $-C(=O)NR_8R_9$,

$-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, each being optionally substituted with one to four substituents independently from R_3, or R_4 is halogen or hydroxy;

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocycloalkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently from R_3.

5-6. (Cancelled)

7. (Original) The stent according to claim 2 wherein the coating comprises a pharmaceutically acceptable carrier.

8. (Original) The stent according to claim 1 wherein the stent is a stent graft.

9. (Original) The stent according to claim 1 wherein the stent comprises a polymer.

10. (Original) The stent according to claim 9 in which the polymer is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, a polymethylmethacrylate, a polyethylene, a poly(ethylene terephthalate), a polyalkylene oxalate, a polyurethane, a polysiloxane, a poly(dimethyl siloxane), a polycyanoacrylate, a polyphosphazene, a poly(amino acid), a ethylene glycol I dimethacrylate, a poly(methyl methacrylate), a poly(2-hydroxyethyl methacrylate), a poly(HEMA),or a polyhydroxyalkanoate compound.

11. (Original) The stent according to claim 2 wherein the coating is a controlled-release coating.

12. (Original) A method for making the stent of claim 2, comprising the step of coating a stent with an effective amount of a JNK Inhibitor.

13. (Original) The method according to claim 12 wherein the stent is a stent graft.

14. (Original) The stent according to claim 3 wherein the material having an effective amount of a JNK Inhibitor incorporated therein allows for controlled-release of the JNK Inhibitor.

15. (Original) A method for making the stent of claim 3, comprising manufacturing a stent with material having an effective amount of a JNK Inhibitor incorporated therein.

16. (Previously presented) A method for treating a cardiovascular or renal disease in a patient, comprising implanting the stent of claim 1 into a patient in need thereof.

17. (Previously presented) A method for treating atherosclerosis in a patient, comprising implanting the stent of claim 1 into a patient in need thereof.

18. (Original) The method of claim 16 further comprising surgical intervention.

19. (Original) The method of claim 17 further comprising surgical intervention.

20. (Original) The method of claim 18 wherein the surgical intervention involves percutaneous coronary intervention, revascularization, percutaneous transluminal coronary angioplasty, carotid percutaneous transluminal angioplasty coronary by-pass grafting or coronary angioplasty with stent implantation.

21. (Original) The method of claim 18 wherein the surgical intervention involves renal angioplasty; peripheral percutaneous transluminal intervention of the iliac, femoral or popliteal arteries; or surgical intervention using impregnated artificial grafts.

22. (Original) The method of claim 16 wherein the stent is a stent graft.

23. (Original) The method of claim 17 wherein the stent is a stent graft.

24. (Original) The method of claim 20 wherein the implanting occurs prior to the administration of angioplasty.

25. (Original) The method of claim 20 wherein the implanting occurs during the administration of angioplasty.

26. (Original) The method of claim 20 wherein the implanting occurs after the administration of angioplasty.

27. (Original) A kit comprising the stent of claim 1 and directions for its use.